Agilent Launches New NanoDis System for Nanoparticle Dissolution Testing
November 23 2020 - 8:00AM
Business Wire
System addresses the pharmaceutical industry’s need for
compliant, semi-automated testing of nanoparticle drug
formulations.
Agilent Technologies Inc. (NYSE: A) today announced the
introduction of the NanoDis System for nanoparticle dissolution
testing. Combining Agilent instrumentation and software to enable
customers to meet 21 CFR Part 11 and other regulations through its
application, the new NanoDis System delivers a dedicated workflow
that is automatable and auditable.
Designed in collaboration with Dr. Emre Türeli from nanoparticle
manufacturer MyBiotech GmbH, the NanoDis System enables R&D
formulation chemists to deliver new formulations into manufacturing
faster, and also allows manufacturing teams to deliver consistent
batches of QC passed new drug products ready for commercial
sale—all in an automated and compliant manner.
"Agilent's introduction of the NanoDis System is significant in
that it is the first nanoparticle testing solution that allows
methods to be easily transferred from R&D to QC, supporting
scientists in meeting the requirements of United States
Pharmacopeia (USP)," said Michael Frank, associate vice president
of global marketing for Agilent’s Liquid Phase Separation division.
"The NanoDis System can be universally implemented, therefore
ensuring that our customers' global laboratory locations deliver
the same results every time. Additionally, the NanoDis System is an
end-to-end, single-vendor solution that is fully supported by a
dedicated global team."
Lifesaving drugs are increasingly being developed using
nanoparticles for targeted drug delivery. These new dosage forms
offer the promise of advancing patient care and treatment
outcomes—particularly for oncology and cardiology patients—by
reducing side-effects and improving drug solubility and
bioavailability. However, nanoparticles can be incredibly difficult
to work with from a dissolution testing perspective. This testing
is a critical regulatory requirement for the development,
manufacturing, and QC of medical drug dosage forms.
“The new NanoDis System gives us a far better insight and
thorough understanding of dissolution of nanoparticles, enabling a
truly efficient formulation development where we can rely on
in-vitro data for the lead formulation selection,” commented Dr.
Emre Türeli, CSO MyBiotech GmbH
The Agilent NanoDis System was selected as a finalist for the
CPhI Pharma Awards for excellence in Pharma: Analysis, Testing and
Quality Control. The awards celebrate the thinkers and creators at
the forefront of driving the pharmaceutical industry forward
through innovation, technology and strategies.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. Now in its
20th year as an independent company delivering insight and
innovation toward improving the quality of life, Agilent
instruments, software, services, solutions, and people provide
trusted answers to customers' most challenging questions. The
company generated revenue of $5.16 billion in fiscal 2019 and
employs 16,300 people worldwide. Information about Agilent is
available at www.agilent.com. To receive the latest Agilent news,
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201123005344/en/
Media Contact Catherine Kaye Agilent Technologies +44 (0)
7775 410632 Catherine.kaye@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024